How long the live shingles vaccine protects you
Official title: Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years or Older: a Multicenter, Retrospective Cohort Study Based on Phase III Trial
Run by Jiangsu Province Centers for Disease Control and Prevention · NCT07585370 · Data updated 2026-11-12
This will see if the live attenuated shingles vaccine keeps adults from the original Phase III trial protected against herpes zoster for up to six years after vaccination.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 24740 (estimated) |
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention Research network |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | March 6, 2026 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07585370 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults who were enrolled in the Phase III trial (NCT04334577), remained herpes zoster–free during that trial (E-mFAS), and can provide verbal informed consent for retrospective follow-up.
✕Probably not a fit
Individuals who developed herpes zoster during the original trial, who died before the retrospective study, or who were not part of the original Phase III cohort are not eligible and will not benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter retrospective cohort study will include 24,740 participants who were non-herpes zoster cases in the modified full analysis set (E-mFAS) from the Phase III trial (NCT04334577) conducted in 2020–2021. Individuals originally randomized 1:1 to receive one dose of the live attenuated zoster vaccine (≥4.3 lg PFU per 0.5 mL) or matched placebo will be compared using a stage-based design to measure cumulative incidence of herpes zoster within six years after vaccination. Stage 1 will compare outcomes between the originally vaccinated and placebo groups using data collected at participating provincial and county CDC sites. People who developed herpes zoster during the original trial or who died before the retrospective follow-up are excluded from this analysis.
Why it matters
Potential benefit: If successful, the results could clarify how long this vaccine protects and inform booster or vaccination policy decisions.
How similar studies have gone: Previous long-term studies of live zoster vaccines (for example Zostavax) have shown initial protection with waning immunity over several years, so the approach is established but long-term effectiveness varies by vaccine and population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals included in the E-mFAS from the Phase III Clinical Trial (NCT04334577) of the live attenuated herpes zoster vaccine produced by Changchun BCHT biotechnology Co. conducted during 2020-2021. 2. Individuals who were able to complete the study with verbal informed consent. Exclusion Criteria: 1. Individuals who developed herpes zoster during the original Phase III Clinical Trial follow-up period. 2. Individuals who were known to have died before the retrospective study.
Where it's running
-
Jiangsu Provincial Center for Diseases Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)
Nanjing, Jiangsu, China Recruiting
Study contacts
- Principal investigator: Pengfei Jin — Jiangsu Provincial Center for Diseases Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)
- Study coordinator: Pengfei Jin
- Email: jpf19891103@163.com
- Phone: #86-25-83759913
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Recombinant Zoster Vaccine with ZFA01 Adjuvant in Adults 40+
A two-part study tests a recombinant herpes zoster vaccine in healthy adults aged 40 and older to see if it boosts immune responses and is safe.
-
Recombinant zoster (Shingrix) to see if it lowers new dementia diagnoses in people 76 and older in Finland.
This trial will test whether the Shingrix shingles vaccine lowers the chance of a new dementia diagnosis in people aged 76 or older who live in Finland.
-
Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia
This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.
-
Lyophilized shingles mRNA vaccine safety and immune response
This trial will test a lyophilized mRNA vaccine to see if it is safe and produces immune responses in adults aged 40 years and older.
-
Loxoprofen patch for relieving shingles pain
This will test if adding a loxoprofen sodium patch to standard care reduces pain in adults with shingles.
-
Baclofen for relieving pain from herpes zoster
We will try baclofen alongside standard care to reduce moderate to severe shingles pain in adults who developed rash within the past 90 days.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.